Analysts Expect BioScrip Inc (NASDAQ:BIOS) to Post -$0.10 EPS

Wall Street analysts forecast that BioScrip Inc (NASDAQ:BIOS) will report earnings per share of ($0.10) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for BioScrip’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.12). BioScrip posted earnings per share of ($0.14) in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The firm is expected to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.16) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for BioScrip.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The company had revenue of $178.96 million during the quarter, compared to the consensus estimate of $179.23 million. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.12) earnings per share.

BIOS has been the topic of several research analyst reports. Barrington Research reissued a “buy” rating and issued a $4.00 price target on shares of BioScrip in a report on Friday, May 3rd. TheStreet cut shares of Red Lion Hotels from a “c” rating to a “d+” rating in a report on Wednesday, April 3rd. Zacks Investment Research raised shares of Hanmi Financial from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Finally, BidaskClub raised shares of WhiteHorse Finance from a “sell” rating to a “hold” rating in a report on Thursday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. BioScrip presently has an average rating of “Buy” and a consensus target price of $4.60.

BioScrip stock traded up $0.07 during trading hours on Friday, hitting $2.85. The company had a trading volume of 1,008,791 shares, compared to its average volume of 996,602. The stock has a market capitalization of $357.95 million, a price-to-earnings ratio of -5.82 and a beta of 0.68. BioScrip has a one year low of $1.56 and a one year high of $4.14. The business’s 50-day moving average is $2.39.

Several institutional investors and hedge funds have recently made changes to their positions in BIOS. Caxton Associates LP acquired a new stake in shares of BioScrip during the 4th quarter worth approximately $52,000. Menta Capital LLC acquired a new stake in shares of BioScrip during the 4th quarter worth approximately $124,000. Perkins Capital Management Inc. boosted its position in shares of BioScrip by 6.5% during the 1st quarter. Perkins Capital Management Inc. now owns 231,000 shares of the company’s stock worth $462,000 after acquiring an additional 14,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of BioScrip by 28.8% during the 4th quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock worth $35,013,000 after acquiring an additional 2,191,490 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of BioScrip by 81.2% during the 4th quarter. Two Sigma Investments LP now owns 767,882 shares of the company’s stock worth $2,741,000 after acquiring an additional 344,013 shares in the last quarter. 78.60% of the stock is currently owned by institutional investors.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Further Reading: QQQ ETF

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.